• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奎尼丁代谢产物对人体电生理反应的作用。

Contribution of quinidine metabolites to electrophysiologic responses in human subjects.

作者信息

Kavanagh K M, Wyse D G, Mitchell L B, Gilhooly T, Gillis A M, Duff H J

机构信息

Department of Medicine, University of Calgary, Alberta, Canada.

出版信息

Clin Pharmacol Ther. 1989 Sep;46(3):352-8. doi: 10.1038/clpt.1989.150.

DOI:10.1038/clpt.1989.150
PMID:2776394
Abstract

The quinidine metabolites 3-hydroxyquinidine, 2'-oxoquinidione, and quinidine-N-oxide and the contaminant dihydroquinidine have been shown to have electrophysiologic activity. This study investigated the time-dependent contributions of quinidine, dihydroquinidine, and the quinidine metabolites to the electrophysiologic effects of a prolonged quinidine infusion in 14 patients referred for management of symptomatic ventricular tachyarrhythmias. Electrophysiologic testing and blood sampling were done at baseline and every 5 minutes throughout a 110-minute quinidine infusion. Changes in ventricular effective refractory periods correlated significantly with serum concentrations of quinidine-N-oxide (r = 0.54; p less than 0.001), 3-hydroxyquinidine (r = 0.50; p less than 0.001), and time (r = 0.52; p less than 0.001) but did not correlate with the quinidine concentrations (r = 0.19). Multiple linear regression revealed that only 3-hydroxyquinidine and time contributed independently to changes in the ventricular effective refractory period. Quinidine concentration was the only variable that contributed independently to changes in ventricular tachycardiac cycle lengths. Time was the only variable that correlated independently with changes in QRS and QTc durations. These data indicate that active metabolites accumulate during an intravenous infusion that attains therapeutic quinidine levels and that quinidine and its metabolites may have different electrophysiologic effects.

摘要

奎尼丁代谢产物3-羟基奎尼丁、2'-氧代奎尼二酮、奎尼丁-N-氧化物以及污染物二氢奎尼丁已被证明具有电生理活性。本研究调查了奎尼丁、二氢奎尼丁和奎尼丁代谢产物对14例因有症状的室性快速性心律失常前来治疗的患者进行长时间奎尼丁输注时电生理效应的时间依赖性作用。在基线时以及在110分钟的奎尼丁输注过程中每隔5分钟进行一次电生理测试和采血。心室有效不应期的变化与奎尼丁-N-氧化物的血清浓度显著相关(r = 0.54;p小于0.001)、与3-羟基奎尼丁的血清浓度显著相关(r = 0.50;p小于0.001)以及与时间显著相关(r = 0.52;p小于0.001),但与奎尼丁浓度不相关(r = 0.19)。多元线性回归显示,只有3-羟基奎尼丁和时间对心室有效不应期的变化有独立贡献。奎尼丁浓度是唯一对室性心动周期长度变化有独立贡献的变量。时间是唯一与QRS和QTc间期变化独立相关的变量。这些数据表明,在静脉输注达到治疗性奎尼丁水平的过程中活性代谢产物会蓄积,并且奎尼丁及其代谢产物可能具有不同的电生理效应。

相似文献

1
Contribution of quinidine metabolites to electrophysiologic responses in human subjects.奎尼丁代谢产物对人体电生理反应的作用。
Clin Pharmacol Ther. 1989 Sep;46(3):352-8. doi: 10.1038/clpt.1989.150.
2
Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine.奎尼丁、其主要代谢产物及二氢奎尼丁的体外电生理学比较
J Pharmacol Exp Ther. 1987 Apr;241(1):84-90.
3
Disposition of 3-hydroxyquinidine in patients receiving initial intravenous quinidine gluconate for electrophysiology testing of ventricular tachycardia.接受初始静脉注射葡萄糖酸奎尼丁以进行室性心动过速电生理检查的患者中3-羟基奎尼丁的处置情况。
DICP. 1989 May;23(5):375-8. doi: 10.1177/106002808902300504.
4
Antiarrhythmic activity of two quinidine metabolites in experimental reperfusion arrhythmia: relative potency and pharmacodynamic interaction with the parent drug.
J Pharmacol Exp Ther. 1987 Oct;243(1):297-301.
5
Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.
Am Heart J. 1987 Feb;113(2 Pt 1):302-6. doi: 10.1016/0002-8703(87)90269-9.
6
[Electrophysiologic effects of intravenous 3-hydroxy-dihydroquinidine (LNC-834) in man].静脉注射3-羟基二氢奎尼丁(LNC-834)对人体的电生理效应
Arch Mal Coeur Vaiss. 1989 Dec;82(12):2035-40.
7
Safety and efficacy of intravenous quinidine.
Am J Med. 1983 Jul;75(1):36-42. doi: 10.1016/0002-9343(83)91165-8.
8
Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes.
Clin Pharmacol Ther. 1988 Jun;43(6):636-42. doi: 10.1038/clpt.1988.88.
9
The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.奎尼丁和3-羟基奎尼丁的药代动力学与药效学。
Br J Clin Pharmacol. 1988 Oct;26(4):415-21. doi: 10.1111/j.1365-2125.1988.tb03400.x.
10
Intravenous quinidine: relations among concentration, tachyarrhythmia suppression and electrophysiologic actions with inducible sustained ventricular tachycardia.
Am J Cardiol. 1985 Jan 1;55(1):92-7. doi: 10.1016/0002-9149(85)90306-6.

引用本文的文献

1
Therapeutic drug monitoring: antiarrhythmic drugs.治疗药物监测:抗心律失常药物
Br J Clin Pharmacol. 1998 Oct;46(4):307-19. doi: 10.1046/j.1365-2125.1998.t01-1-00768.x.
2
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.奎宁、氯喹和阿莫地喹的药代动力学。临床意义。
Clin Pharmacokinet. 1996 Apr;30(4):263-99. doi: 10.2165/00003088-199630040-00002.
3
Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.IA类抗心律失常药物中毒。奎尼丁、普鲁卡因胺和丙吡胺。
Drug Saf. 1990 Nov-Dec;5(6):393-420. doi: 10.2165/00002018-199005060-00002.